Bristol-Myers Squibb Company (BMY)vsSouthern Copper Corporation (SCCO)
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
SCCO
Southern Copper Corporation
$185.29
+3.20%
BASIC MATERIALS · Cap: $148.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 233% more annual revenue ($48.48B vs $14.55B). SCCO leads profitability with a 34.1% profit margin vs 15.0%. SCCO appears more attractively valued with a PEG of 5.41. SCCO earns a higher WallStSmart Score of 65/100 (B-).
BMY
Buy60
out of 100
Grade: C+
SCCO
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Intrinsic value data unavailable for SCCO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Every $100 of equity generates 46 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 58.3%
Revenue surging 36.2% year-over-year
Earnings expanding 66.7% YoY
Large-cap with strong market position
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 13.0x book value
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : SCCO
The strongest argument for SCCO centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 34.1% and operating margin at 58.3%. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : SCCO
The primary concerns for SCCO are P/E Ratio, Price/Book, PEG Ratio.
Key Dynamics to Monitor
BMY profiles as a value stock while SCCO is a growth play — different risk/reward profiles.
SCCO carries more volatility with a beta of 1.08 — expect wider price swings.
SCCO is growing revenue faster at 36.2% — sustainability is the question.
SCCO generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
SCCO scores higher overall (65/100 vs 60/100), backed by strong 34.1% margins and 36.2% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Southern Copper Corporation
BASIC MATERIALS · COPPER · USA
Southern Copper Corporation is engaged in the extraction, exploration, smelting and refining of copper and other minerals in Peru, Mexico, Argentina, Ecuador and Chile.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?